FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number:	3235-0287									
Expires:	December 31, 2014									
Estimated average burden										
hours per response:	0.5									

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Yanchik Joseph A., III						2. Issuer Name and Ticker or Trading Symbol Tokai Pharmaceuticals Inc [TKAI]								Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owner					
(Last)	,	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/17/2015									Officer (give title below)			Other (s	
C/O TOKAI PHARMACEUTICALS, INC. 255 STATE STREET, 6TH FLOOR					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	N M	Α ()2109											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	tate) (Zip)																
		Tab	le I - N	on-Deriv	ative S	Sec	urities	s Ac	quired, D	isp	osed o	of, or Be	enefici	ally	Owne	d			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					Execution Date,			Code (Ins	Transaction Dispos Code (Instr. and 5)		rities Acqued Of (D) (4 Securit Benefit Owned		ties F cially (I		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount (A) or (D)		or Pric	e	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(111501 . 4)	
		Ta	able II						uired, Dis , options,						wned				
1. Title of Derivative Security (Instr. 3) 2. Conversio or Exercise Price of Derivative Security			3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of		6. Date Exercisable Expiration Date (Month/Day/Year)			Amount of		of Dei Sec	erivative ecurity istr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercisable	Ex _l	oiration te	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$14.04	06/17/2015			A		12,000		(1)	06/	16/2025	Common Stock	12,000) (\$0.00	12,000		D	

Explanation of Responses:

1. This option vests with respect to 100% of the shares underlying the option on June 17, 2016 subject to his continued service on Tokais Board of Directors.

Remarks:

/s/ Cindy Driscoll, Attorneyin-Fact
** Signature of Reporting Person

06/19/2015

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).